INT240922

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2008
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 0.51
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Cpt1a) mitochondrion (Cpt1a) transferase activity, transferring acyl groups (Cpt1a)
lipid metabolic process (Cpt1a)
Cpt1a (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 34 5.68 Low Low
Bile 78 5.00 Very Low Very Low Very Low
agonist 19 5.00 Very Low Very Low Very Low
antagonist 14 5.00 Very Low Very Low Very Low
Crohn's disease 12 5.00 Very Low Very Low Very Low
tolerance 8 5.00 Very Low Very Low Very Low
antidepressant 6 5.00 Very Low Very Low Very Low
dexamethasone 4 5.00 Very Low Very Low Very Low
Taxol 4 5.00 Very Low Very Low Very Low
anticonvulsant 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Repression 6 93.36 High High
Diabetes Mellitus 26 62.32 Quite High
Insulin Resistance 14 61.56 Quite High
Obesity 8 60.64 Quite High
Dyslipidemia /

Combined Dyslipidemia

1 50.00 Quite Low
Lipidosis 3 34.24 Quite Low
Glycosuria 1 16.28 Low Low
Polyuria 1 15.64 Low Low
INFLAMMATION 24 5.68 Low Low
Inflammatory Bowel Disease 64 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
-oxidation by upregulating transcription of genes including mitochondrial 3-hydroxy-3-methylglutartate-CoA synthase 2 (HMGCS2) and carnitine palmitoyltransferase 1A (CPT1A) during fasting or after prolonged exercise [Wolfrum et al., 2004].
Transcription (transcription) of CPT1A
1) Confidence 0.36 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.12 Pain Relevance 0
Reduced CPT-1 mRNA levels in PEPCK-C–silenced animals, together with increased malonyl-CoA content, a potent allosteric inhibitor of CPT-1, provide indirect evidence for a slight inhibition of fatty acid oxidation.
Transcription (levels) of CPT-1
2) Confidence 0.29 Published 2008 Journal Diabetes Section Body Doc Link PMC2494684 Disease Relevance 0.24 Pain Relevance 0
Using wild-type and SXR-/- mice, they showed that treatment with PCN reduced steady-state mRNA levels of HMGCS2 and CPT1A in wild-type, but not in SXR-deficient mice.
Transcription (levels) of CPT1A
3) Confidence 0.27 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.14 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox